Evaxion A/S Files October 2025 6-K Report
Ticker: EVAX · Form: 6-K · Filed: Oct 6, 2025 · CIK: 1828253
| Field | Detail |
|---|---|
| Company | Evaxion A/S (EVAX) |
| Form Type | 6-K |
| Filed Date | Oct 6, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: 6-K, foreign-private-issuer, reporting
TL;DR
Evaxion A/S filed its October 6-K, confirming its foreign private issuer status and 20-F annual report filings.
AI Summary
Evaxion A/S, a biotechnology company, filed a Form 6-K on October 6, 2025, for the month of October 2025. The filing is a report of a foreign private issuer and indicates that the company files annual reports under Form 20-F. The company's principal executive office is located in Hoersholm, Denmark.
Why It Matters
This filing provides routine updates for investors and stakeholders regarding Evaxion A/S's status as a foreign private issuer and its reporting obligations.
Risk Assessment
Risk Level: low — This filing is a routine administrative report and does not contain significant new financial or operational information that would typically alter risk.
Key Numbers
- 20251006 — Filing Date (Date the 6-K was filed with the SEC.)
- October 2025 — Reporting Period (The month for which this report is filed.)
Key Players & Entities
- Evaxion A/S (company) — Registrant
- Evaxion Biotech A/S (company) — Former company name
- 001-39950 (dollar_amount) — Commission File Number
FAQ
What type of company is Evaxion A/S?
Evaxion A/S is a biotechnology company specializing in biological products, as indicated by its SIC code 2836.
What is the purpose of a Form 6-K filing?
A Form 6-K is a Report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, used to provide information that the company may be required to disclose to its home country security holders.
Does Evaxion A/S file annual reports under Form 20-F?
Yes, the filing explicitly indicates with a checkmark that Evaxion A/S files annual reports under cover of Form 20-F.
Where is Evaxion A/S's principal executive office located?
Evaxion A/S's principal executive office is located at Dr. Neergaards Vej 5f, DK-2970 Hoersholm, Denmark.
When did Evaxion A/S change its name?
The company formerly known as Evaxion Biotech A/S changed its name to Evaxion A/S on October 14, 2020.
Filing Stats: 324 words · 1 min read · ~1 pages · Grade level 10.6 · Accepted 2025-10-06 06:03:38
Filing Documents
- f6k_100325.htm (6-K) — 7KB
- exh_991.htm (EX-99.1) — 7KB
- 0001171843-25-006276.txt ( ) — 15KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Evaxion A/S (Registrant) Date: October 3, 2025 By: /s/ Birgitte Rn Birgitte Rn Interim Chief Executive Officer